Company intelligence / Profile preview

Curadh MTR Inc.

Pennsylvania, United Statescuradhmtr.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Curadh is advancing a pipeline of next-generation radiopharmaceutical therapies targeting solid tumors. The company has completed proof-of-principle studies and anticipates first-in-human clinical trials in 2025–26. Its lead program targets an undisclosed high-value target with broad applications in oncology. The company leverages strategic partnerships for isotope supply and manufacturing, focusing on fast-to-clinic opportunities using innovative isotopes on validated oncology targets[2][3].

Therapeutic areas: Oncology
Modalities: Radiopharmaceuticals (Molecularly Targeted Radiation Therapies)Biologicals/biologics (novel biological programs)
Industry: Biotech

Partnerships

NorthStar Medical Radioisotopes (strategic collaboration for Actinium‑225 supply & development)[4]SHINE Technologies (long-term supply agreement for Lutetium‑177 & Terbium‑161 isotopes)[5]

Beyond the preview

Go deeper on Curadh MTR Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curadh MTR Inc..

Explore the full profile